News & Updates

SLPI deficiency in cystic fibrosis much worse in P aeruginosa-infected female patients

25 May 2023

The presence of Pseudomonas aeruginosa worsens an already deficient airway secretory leukocyte protease inhibitor (SLPI), an antiprotease that helps prevent tissue damage, in patients with cystic fibrosis (CF), reports a study. Moreover, female patients show markedly lower SLPI levels than males.

SLPI deficiency in cystic fibrosis much worse in P aeruginosa-infected female patients

25 May 2023

Sofosbuvir/velpatasvir effective, safe for paediatric HCV

25 May 2023 by

The direct-acting antiviral (DAA) sofosbuvir/velpatasvir (SOF/VEL) was effective and safe for the treatment of chronic hepatitis C virus (HCV) infection in individuals aged 6–18 years, the PANDAA-PED study has shown.

Sofosbuvir/velpatasvir effective, safe for paediatric HCV

25 May 2023

2-dose, 3-dose vax schedules active against several meningococcal serogroup B strains

25 May 2023 by

Both the 2-dose and 3-dose vaccination schedules of the four-component meningococcal serogroup B vaccine (4CMenB) appear to provide protection against a panel epidemiologically relevant strains in adolescents and young adults, according to a phase III study presented at ESPID 2023.

2-dose, 3-dose vax schedules active against several meningococcal serogroup B strains

25 May 2023

Dynamic hyperinflation decreases after EBVs treatment

24 May 2023

Endobronchial valves (EBVs) treatment results in a decrease in dynamic hyperinflation (DH), as shown in a study, which notes the association of such improvement with static changes.

Dynamic hyperinflation decreases after EBVs treatment

24 May 2023

Frequent hospitalization burdens children with chronic conditions

24 May 2023 by

Complex chronic conditions (CCCs) in children are associated with numerous brief hospitalizations, with a high rate of readmissions, according to a study presented at PAS 2023.

Frequent hospitalization burdens children with chronic conditions

24 May 2023

Fibromyalgia symptoms weakly predict RA activity after treatment

24 May 2023

Higher levels of fibromyalgia (FM) symptoms in patients with rheumatoid arthritis (RA) are slightly indicative of worse disease activity following treatment with a disease-modifying antirheumatic drug (DMARD), suggest the results a recent study.

Fibromyalgia symptoms weakly predict RA activity after treatment

24 May 2023

TAK-003 elicits cellular immune response against all dengue serotypes in paediatric cohort

24 May 2023 by

TAK-003, a live-attenuated, recombinant tetravalent dengue vaccine covering all four dengue virus (DENV) strains, elicited a cell-mediated immune (CMI) response in healthy children and adolescents aged 4–16 years, the phase II DEN-313 study has shown.

TAK-003 elicits cellular immune response against all dengue serotypes in paediatric cohort

24 May 2023

Vedolizumab prevents postop CD recurrence: new indication likely

24 May 2023 by

Patients with resected Crohn’s disease (CD) who were treated with the gut-selective α4β7-integrin inhibitor vedolizumab were less likely to have endoscopic signs of recurrence compared with placebo in the Reprevio study presented at DDW 2023.

Vedolizumab prevents postop CD recurrence: new indication likely

24 May 2023

Pulsed field ablation benefits most patients with AF treated in usual clinical care

23 May 2023

Catheter ablation using pulsed field energy leads to freedom from atrial arrhythmia in many patients with atrial fibrillation (AF), according to data from MANIFEST-PF*.

Pulsed field ablation benefits most patients with AF treated in usual clinical care

23 May 2023

Fexuprazan brings relief in erosive esophagitis, noninferior to esomeprazole

23 May 2023 by

The novel potassium-competitive acid blocker fexuprazan shows comparable safety and efficacy to the proton pump inhibitor esomeprazole in the treatment of Chinese patients with erosive esophagitis, as shown in the results of a phase III study presented at DDW 2023.

Fexuprazan brings relief in erosive esophagitis, noninferior to esomeprazole

23 May 2023

News & Updates

Filter by Specialty:

Specialty:

SLPI deficiency in cystic fibrosis much worse in P aeruginosa-infected female patients

SLPI deficiency in cystic fibrosis much worse in P aeruginosa-infected female patients

Sofosbuvir/velpatasvir effective, safe for paediatric HCV

Sofosbuvir/velpatasvir effective, safe for paediatric HCV

2-dose, 3-dose vax schedules active against several meningococcal serogroup B strains

2-dose, 3-dose vax schedules active against several meningococcal serogroup B strains

Dynamic hyperinflation decreases after EBVs treatment

Dynamic hyperinflation decreases after EBVs treatment

Frequent hospitalization burdens children with chronic conditions

Frequent hospitalization burdens children with chronic conditions

Fibromyalgia symptoms weakly predict RA activity after treatment

Fibromyalgia symptoms weakly predict RA activity after treatment

TAK-003 elicits cellular immune response against all dengue serotypes in paediatric cohort

TAK-003 elicits cellular immune response against all dengue serotypes in paediatric cohort

Vedolizumab prevents postop CD recurrence: new indication likely

Vedolizumab prevents postop CD recurrence: new indication likely

Pulsed field ablation benefits most patients with AF treated in usual clinical care

Pulsed field ablation benefits most patients with AF treated in usual clinical care

Fexuprazan brings relief in erosive esophagitis, noninferior to esomeprazole

Fexuprazan brings relief in erosive esophagitis, noninferior to esomeprazole